Updated: Reddy's Follows Endo On US Kuvan Launch

Sapropterin Market Worth Roughly $500m

 
• By Dean Rudge
  
Red_Rocket
Both Endo and Reddy's have now launched generic Kuvan tablets following patent-litigation settlements • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Products

More from Generics Bulletin